GoodRx Holdings, Inc. Class A (GDRX)

44.13
2.20 4.75
NASDAQ
Prev Close 46.33
Open 46.26
Day Low/High 43.87 / 46.36
52 Wk Low/High 26.66 / 64.22
Volume 1.68M
Exchange NASDAQ
Shares Outstanding 395.64B
Market Cap 18.01B
Div & Yield N.A. (N.A)

Brick and Mortar strikes back.

I'm focusing on the active consumers and subscription plans as it gives us a view of the future.

Avoid the long side of GDRX until we see evidence of a durable bottom.

Have the charts improved over the last few months?

We can still look forward to that always elusive 'follow through' day for the Nasdaq.

IPOs in recent months have done extremely well -- not so GDRX.

Traders have to take the extra step to understand the underlying company and sector before jumping into a position.

The good news is that my trade offered an opportunity for a quick profit. The bad news is it didn't last very long.

Trading volume was low enough Wednesday to indicate a lack of conviction, or conviction that did not spread across enough managers to truly change the narrative.

Definitely put this one on the highly speculative side.

GDRX will not stay in a tight range for long.

Jim Cramer: The Days of Amazon as Death Star Are Over

Jim Cramer: The Days of Amazon as Death Star Are Over

Brick and Mortar strikes back.

Staying Smaller and Tighter With This GoodRx Trade

Staying Smaller and Tighter With This GoodRx Trade

I'm focusing on the active consumers and subscription plans as it gives us a view of the future.

GoodRx Isn't Showing Us a Good Stock Chart

GoodRx Isn't Showing Us a Good Stock Chart

Avoid the long side of GDRX until we see evidence of a durable bottom.

Let's Checkup on GoodRx

Let's Checkup on GoodRx

Have the charts improved over the last few months?

Doors and Catalysts, Nasdaq Resistance, China Trouble? Trading Defense Stocks

Doors and Catalysts, Nasdaq Resistance, China Trouble? Trading Defense Stocks

We can still look forward to that always elusive 'follow through' day for the Nasdaq.

GoodRx Needs a Shot in the Arm to Improve Its Outlook

GoodRx Needs a Shot in the Arm to Improve Its Outlook

IPOs in recent months have done extremely well -- not so GDRX.

Out for a Scalp? Not So Fast

Out for a Scalp? Not So Fast

Traders have to take the extra step to understand the underlying company and sector before jumping into a position.

I'll Take My Medicine on GoodRx

I'll Take My Medicine on GoodRx

The good news is that my trade offered an opportunity for a quick profit. The bad news is it didn't last very long.

Indecisive Markets, RealClearPolitics, Infection Surge, Moderna, Disney Earnings

Indecisive Markets, RealClearPolitics, Infection Surge, Moderna, Disney Earnings

Trading volume was low enough Wednesday to indicate a lack of conviction, or conviction that did not spread across enough managers to truly change the narrative.

GoodRX Has Struggled to Gain Momentum but That May Be Changing

GoodRX Has Struggled to Gain Momentum but That May Be Changing

Definitely put this one on the highly speculative side.

GoodRx Hasn't Been Public Long But Here's What We Know

GoodRx Hasn't Been Public Long But Here's What We Know

GDRX will not stay in a tight range for long.